Wang Z, Zhu S, Zhao J, et al. - Abiraterone showed better efficacy in patients with intraductal carcinoma of the prostate (IDC-P) of either pattern compared to docetaxel. Nevertheless, IDC-P pattern 2 responded unsatisfactorily to either abiraterone or docetaxel therapy. Novel therapeutic strategies for IDC-P pattern 2 need future studies.

• In 91/170 (53.5%) patients, IDC-P was confirmed.

• As per the findings, 36/91 (39.6%) and 55/91 (60.4%) harbored IDC-P patterns 1 and 2, respectively among them.

• The results demonstrated that individuals with IDC-P pattern 1 shared similar clinical outcomes to those without IDC-P in both abiraterone and docetaxel treatment.

• Nevertheless, it has been reported that against cases without IDC-P or with IDC-P pattern 1, patients with IDC-P pattern 2 had a markedly poorer prognosis in either abiraterone (mPSA-PFS: 11.9 vs. 11.1 vs. 6.1 months, p < 0.001; mrPFS: 18.9 vs. 19.4 vs. 9.6 months, p < 0.001) or docetaxel (mPSA-PFS: 6.2 vs. 6.6 vs. 3.0 months, p < 0.001; mrPFS: 15.1 vs. 12.6 vs. 5.5 months, p < 0.001) treatment.

• Docetaxel had comparable therapeutic efficacy with abiraterone for patients without IDC-P.

• However, in patients with either IDC-P pattern 1 or pattern 2, the efficacy of docetaxel was significantly inferior to abiraterone.